A comprehensive view of Ridgeback Biotherapeutics LP. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

A committee of the European Medicines Agency recommends against approval of Merck and Ridgeback Biotherapeutics’ Lagevrio COVID-19 pill because clinical benefit 'could not be demonstrated'; Lagevrio approved in US, UK, Japan, China and other countries

FDA ends positive test requirement to prescribe Paxlovid COVID-19 treatment to adult and pediatric patients, Lagevrio to adults at risk of progressing to severe COVID-19; FDA still recommends using SARS-CoV-2 viral testing to diagnose COVID-19

Emergent Biosolutions to manufacture, distribute Ridgeback Biotherapeutics’ Ebola injectable antibody therapy Ebanga ansuvimab-zykl in US, Canada; Ridgeback to remain global access partner for Ebanga in endemic countries

HHS reports sales of Pfizer’s COVID-19 oral antiviral Paxlovid outpaced drugs from other firms; 162,000 Paxlovid courses used in US in past week compared to 20,000 courses of Merck and Ridgeback’s Lagevrio, 16,000 courses of AstraZeneca’s Evusheld

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count